SCHEMBL69580

SCHEMBL69580

CCCCCc1ccc(O)c(O)c1

nearest known ligand 0.96

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 7/20 0.79
ALOX15 P16050 7/20 0.79
IAPP P10997 1/20 0.64
KAT8 Q9H7Z6 2/20 0.62
PPARA Q07869 1/20 0.62
CYP3A4 P08684 2/20 0.59
HIF1A Q16665 2/20 0.59
HSD17B10 Q99714 2/20 0.59
CYP2D6 P10635 1/20 0.59
DRD2 P14416 1/20 0.59
TSHR P16473 1/20 0.59
NFKB1 P19838 1/20 0.59
DRD1 P21728 1/20 0.59
DRD4 P21917 1/20 0.59
DRD5 P21918 1/20 0.59
ADRA1D P25100 1/20 0.59
ADRA1A P35348 1/20 0.59
ADRA1B P35368 1/20 0.59
DRD3 P35462 1/20 0.59
TRPA1 O75762 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38660230 0.98 IGF1R (0.76) IGF1RALOX15IAPPKAT8PPARA
SCHEMBL10352944 0.98 IGF1R (0.76) IGF1RALOX15IAPPKAT8PPARA
SCHEMBL7761737 0.98 IGF1R (0.76) IGF1RALOX15IAPPKAT8PPARA
SCHEMBL2782711 0.98 IGF1R (0.76) IGF1RALOX15IAPPKAT8PPARA
SCHEMBL9447274 0.98 IGF1R (0.76) IGF1RALOX15IAPPKAT8PPARA
SCHEMBL11616856 0.98 IGF1R (0.76) IGF1RALOX15IAPPKAT8PPARA
SCHEMBL70343 0.98 IGF1R (0.76) IGF1RALOX15IAPPKAT8PPARA
SCHEMBL68207 0.98 IGF1R (0.76) IGF1RALOX15IAPPKAT8PPARA
SCHEMBL11721061 0.98 IGF1R (0.76) IGF1RALOX15IAPPKAT8PPARA
SCHEMBL30451791 0.98 IGF1R (0.76) IGF1RALOX15IAPPKAT8PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10202474-B2 Process for producing polydienes BRIDGESTONE CORPORATION (JP) 2019-02-12 US claimed
US-20170073443-A1 PROCESS FOR PRODUCING POLYDIENES BRIDGESTONE CORPORATION (US) 2017-03-16 US claimed
US-4894139-A Methods for deactivating copper in hydrocarbon fluids BETZ LABORATORIES, INC. (US) 1990-01-16 US claimed
US-12473454-B2 Water-based extrusion primer for polyethylene HENKEL AG & CO. KGAA (DE) 2025-11-18 US disclosed
US-12227668-B2 Use of preformed reaction products of catechol compounds and functionalized co-reactant compounds to reduce oxidation of bare metal surfaces HENKEL AG & CO. KGAA (DE) 2025-02-18 US disclosed
EP-3559312-B1 REACTION PRODUCTS OF CATECHOL COMPOUNDS AND FUNCTIONALIZED CO-REACTANT COMPOUNDS FOR METAL PRETREATMENT APPLICATIONS HENKEL AG & CO KGAA (DE) 2024-04-24 EP disclosed
EP-3558667-B1 TREATMENT OF CONVERSION-COATED METAL SUBSTRATES WITH PREFORMED REACTION PRODUCTS OF CATECHOL COMPOUNDS AND FUNCTIONALIZED CO-REACTANT COMPOUNDS HENKEL AG & CO KGAA (DE) 2024-03-20 EP disclosed
US-11891534-B2 Treatment of conversion-coated metal substrates with preformed reaction products of catechol compounds and functionalized co-reactant compounds HENKEL AG & CO. KGAA (DE) 2024-02-06 US disclosed
US-11576413-B2 Compositions comprising ionized cannabidiol Natural Extraction Systems, LLC (US) 2023-02-14 US disclosed
CN-113454174-B Water-based extrusion primer for polyethylene 汉高股份有限及两合公司 2023-01-24 CN disclosed
CN-110100045-B Reaction products of catechol compounds with functionalized co-reactive compounds for metal pretreatment applications 汉高股份有限及两合公司 2022-09-06 CN disclosed
EP-0962439-A1 Process and apparatus for producing dihydric phenolic compound UBE INDUSTRIES, LTD. (JP) 1999-12-08 EP disclosed
EP-0954297-A1 USE OF BISPHENOLIC COMPOUNDS TO TREAT TYPE II DIABETES SHAMAN PHARMACEUTICALS, INC. (US) 1999-11-10 EP disclosed
WO-1998015266-A1 USE OF BISPHENOLIC COMPOUNDS TO TREAT TYPE II DIABETES SHAMAN PHARMACEUTICALS, INC. (US) 1998-04-16 WO disclosed
US-5214034-A Improved secretion of nerve growth factor MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1993-05-25 US disclosed
US-5102906-A Alzheimer*s disease MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1992-04-07 US disclosed
EP-0261977-B1 CATECHOL DERIVATIVES, AND PREVENTIVE AND REMEDIAL PREPARATIONS FOR REGRESSIVE DISORDERS IN THE CENTRAL NERVOUS SYSTEM MITSUI TOATSU CHEMICALS, Inc. (JP) 1992-03-04 EP disclosed
US-4985458-A TREATMENT OF ALZHEIMER*S DISEASE MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1991-01-15 US disclosed
EP-0261977-A2 Catechol derivatives, and preventive and remedial preparations for regressive disorders in the central nervous system MITSUI TOATSU CHEMICALS, Inc. (JP) 1988-03-30 EP disclosed
US-3997565-A METAL COMPLEXING AGENT, DISPERSANT, CARBON BLACK, VIRICIDE E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11576413-B2 Compositions comprising ionized cannabidiol CNR1, CNR2, PLCB3 IGF1R 3161/4885ALOX15 811/4885IAPP 1778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.